Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
- Designed for laboratories that provide HLA‑B*57:01 testing to identify risk of hypersensitivity to abacavir and HLA-B*15:02 testing to identify risk of hypersensitivity to carbamazepine. The intended response is qualitative (presence/absence of the allele). This Survey is not appropriate for laboratories that perform molecular HLA typing. For HLA typing proficiency testing, please consult the HLA Molecular Typing (DML) Survey.
- Three 25.0‑μg extracted DNA specimens
- Includes allele detection (genotyping) and/or interpretive challenges
Shipment A: April 20
Shipment B: September 14